Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Faber

Showing results (151-160 of 195) with videos related to

Pageof 20
Sort By:
Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Molecular Cancer Therapeutics|July 28, 2021
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing SarcomaDaniel A R Heisey, Sheeba Jacob, Timothy L Lochmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2009
Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in miceMarielle A Otten, Tom W L Groeneveld, Roelof Flierman, et al.
Cancer Letters|March 1, 2014
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancerJatin Roper, Mark J Sinnamon, Erin M Coffee, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Daraxonrasib (RMC-6236) is an effective targeted therapy for <i>RAS</i> -mutant neuroblastomaRonald D Hill, Krista M Dalton, Richard Kurupi, et al.
The Journal of Experimental Medicine|February 14, 2018
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancerKevin Shee, Wei Yang, John W Hinds, et al.
Spine Deformity|December 2, 2022
The risk of delayed spinal cord injury in pediatric spinal deformity surgeryJ P H J Rutges, J J M Renkens, D H R Kempen, et al.
Biomarkers in Medicine|December 2, 2025
Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studiesRavindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, et al.
Pageof 20

Showing results (151-160 of 195) with videos related to

Sort By:
Pageof 20
Cancer Research|March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancersAaron N Hata, Alan Yeo, Anthony C Faber, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Cancer Research|March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationBirgit Schoeberl, Anthony C Faber, Danan Li, et al.
Molecular Cancer Therapeutics|July 28, 2021
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing SarcomaDaniel A R Heisey, Sheeba Jacob, Timothy L Lochmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2009
Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in miceMarielle A Otten, Tom W L Groeneveld, Roelof Flierman, et al.
Cancer Letters|March 1, 2014
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancerJatin Roper, Mark J Sinnamon, Erin M Coffee, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Daraxonrasib (RMC-6236) is an effective targeted therapy for <i>RAS</i> -mutant neuroblastomaRonald D Hill, Krista M Dalton, Richard Kurupi, et al.
The Journal of Experimental Medicine|February 14, 2018
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancerKevin Shee, Wei Yang, John W Hinds, et al.
Spine Deformity|December 2, 2022
The risk of delayed spinal cord injury in pediatric spinal deformity surgeryJ P H J Rutges, J J M Renkens, D H R Kempen, et al.
Biomarkers in Medicine|December 2, 2025
Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studiesRavindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, et al.
Pageof 20